PR Newswire Clinical TrialsOriginal article
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
Phase 2BGE-102Positive
AI Analysis
Summary
BioAge Labs, in partnership with HitGen, has dosed the first participant in the Phase 2 QUELL-CV trial of BGE-102, a novel oral NLRP3 inhibitor for cardiovascular risk reduction developed using HitGen's DEL technology platform.
Clinical Trial Data
Phase
Phase 2
Outcome Details
First participant dosed in QUELL-CV Phase 2 proof-of-concept trial
Importance:6/10
Sentiment:
0.60
NLRP3 inhibitorcardiovascularoral small moleculeDEL technologybrain-penetrant
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 14, 2026 1:30 PM